No Data
No Data
Shenzhen Kangtai Biological Products (300601.SZ): major shareholder, actual controller, shareholders with more than 5% shareholding, some directors, supervisors, and senior management promise not to reduce their shareholding in the company.
On June 19, GeLongHui reported that Shenzhen Kangtai Biological Products (stock code: 300601.SZ) recently received a commitment letter from its controlling shareholder, actual controller, and chairman Mr. Du Weimin, shareholder Ms. Yuan Liping holding more than 5% of the shares, vice chairman Mr. Wen Feidong, director and president Mr. Miao Xiang, chairman of the supervisory committee Mr. Lu Zhiyun, CFO Ms. Zhou Hui, and board secretary Ms. Tao Jin regarding not reducing the company's shareholding.
Shenzhen Kangtai Biological Products (300601.SZ) has developed some products using synthetic biology-related technology platforms.
Kangtai Biological (300601.SZ) stated on the investor interaction platform on June 7th that the development of some of the company's products involves synthetic biology-related technology platforms, such as recombinant hepatitis B vaccines; and the development of new synthetic biology products such as respiratory syncytial virus (RSV) vaccines, herpes zoster vaccines, etc. is being pushed forward as planned.
Shenzhen Kangtai Biological Products (300601.SZ) will distribute 10 bonus shares and 2 yuan per share for the 2023 equity, with a registration date of June 13.
Kangtai Biological Products (300601.SZ) announced on June 5th that the company's annual equity distribution plan for 2023 is as follows: based on the total share capital on the day of equity registration determined in the announcement of the implementation of the annual equity distribution in 2023, the company will distribute cash dividends (including tax) of RMB 2.000000 per 10 shares to all shareholders from undistributed profits. The equity registration date for this distribution is June 13, 2024, and the ex-rights and ex-dividend date is June 14, 2024.
Is The Market Rewarding Shenzhen Kangtai Biological Products Co., Ltd. (SZSE:300601) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
Shenzhen Kangtai Biological Products (SZSE:300601) has had a rough three months with its share price down 21%. It is possible that the markets have ignored the company's differing financials and dec
Kangtai Biology (300601.SZ): The quadrivalent influenza virus lysis vaccine added clinical trial applications for people aged 6-35 months were accepted
Gelonghui, May 20, 丨 Kangtai Biotech (300601.SZ) announced that the company recently received an acceptance notice issued by the State Drug Administration, agreeing to accept clinical trial applications for the quadrivalent influenza virus lysis vaccine developed by the company in people aged 6-35 months. The company's quadrivalent influenza virus lysis vaccine (for people aged 3 years and above) is currently in phase I and III clinical trials. The current clinical trial application for the company's quadrivalent influenza virus lysis vaccine for people aged 6-35 months has been accepted. The quadrivalent influenza virus lysis vaccine can stimulate the body to develop immunity against the influenza virus and is used to prevent vaccine-related influenza diseases
Impressive Earnings May Not Tell The Whole Story For Shenzhen Kangtai Biological Products (SZSE:300601)
Unsurprisingly, Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) stock price was strong on the back of its healthy earnings report. However, we think that shareholders may be missing so
No Data